Voyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Rock Ventures Iii L.P. Third Sells 55,000 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Rock Ventures Iii L.P. Third sold 55,000 shares of the business’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $9.06, for a total value of $498,300.00. Following the completion of the transaction, the insider now owns 5,273,933 shares of the company’s stock, valued at $47,781,832.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Rock Ventures Iii L.P. Third also recently made the following trade(s):

• On Friday, January 20th, Rock Ventures Iii L.P. Third sold 100,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $9.15, for a total value of $915,000.00.

Voyager Therapeutics Stock Up 3.5 %

Shares of NASDAQ VYGR opened at $9.48 on Wednesday. Voyager Therapeutics, Inc. has a 52-week low of $2.74 and a 52-week high of $10.81. The firm has a fifty day moving average of $6.64 and a 200-day moving average of $6.31. The stock has a market capitalization of $365.99 million, a PE ratio of -20.61 and a beta of 0.92.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.64. Voyager Therapeutics had a negative net margin of 24.21% and a negative return on equity of 21.97%. The company had revenue of $41.09 million during the quarter, compared to analysts’ expectations of $21.25 million. Equities research analysts expect that Voyager Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently made changes to their positions in VYGR. Armistice Capital LLC boosted its position in Voyager Therapeutics by 32.4% during the 3rd quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after purchasing an additional 832,000 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Voyager Therapeutics by 1,735.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 827,950 shares of the company’s stock worth $4,893,000 after purchasing an additional 782,850 shares during the period. Millennium Management LLC boosted its position in Voyager Therapeutics by 291.0% during the 2nd quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after purchasing an additional 616,814 shares during the period. Point72 Asset Management L.P. purchased a new stake in Voyager Therapeutics during the 3rd quarter worth $1,713,000. Finally, Marshall Wace LLP purchased a new stake in Voyager Therapeutics during the 3rd quarter worth $1,123,000. 59.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, November 14th.

About Voyager Therapeutics

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.